Topics:

Multiple Myeloma

Multiple Myeloma

The novel experimental drug sotatercept increased bone mineral density and bone formation in patients with osteolytic lesions of multiple myeloma who had not used bisphosphonates, a phase II study showed.

Results of a new study indicate that half of patients with multiple myeloma were referred to specialist palliative care.

Pomalidomide, an immunomodulatory drug, combined with low-dose dexamethasone improved progression-free survival in patients with refractory or relapsed and refractory multiple myeloma compared with standard of care high-dose dexamethasone, according to a new study.

Myelomas that “lack” a monoclonal protein can be divided further into those that produce some protein and yet do not secrete it or whose serum concentration is so low that it cannot be measured, and those that truly produce no monoclonal protein at all.

To define the differences between the subtypes of myeloma patients, not only prospective collection of clinical and laboratory data are needed, but also cytogenetics and molecular profiling.

Numerous small series of patients suggest that the prognosis for non-secretory myeloma patients is likely no worse than the prognosis for patients with traditional secretory myeloma, and in some settings may be superior.

The use of newer methods of disease assessment that focus on minimal residual disease may facilitate the long-term evaluation of IgD and IgE myeloma patients, even if the rare Ig subtype is not identified at diagnosis.

Pages

Subscribe to Multiple Myeloma on [sitename]

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

By clicking Accept, you agree to become a member of the UBM Medica Community.